BIVI
BIOVIE INC.
NASDAQ · Healthcare · Biotechnology · US
$1.26
−27.17%Nov 4, 2026, 13:00 UTC
BioVie announced a registered direct offering to a single healthcare-focused institutional investor of 2,962,500 shares or common stock equivalents at $1.60 per share.
Source:Oct 26, 2026, 12:00 UTC
BioVie announced that it was invited to present data on bezisterim in long COVID at the 2026 RECOVER-TLC Hybrid Workshop, scheduled for November 4–5 in Bethesda, Maryland.
Oct 14, 2026, 13:52 UTC
BioVie said its abstracts on Phase 2 trial results for bezisterim in Long COVID and Parkinson’s disease were accepted as poster presentations at the American Neurological Association’s annual meeting, scheduled for October 17–20 in San Diego.
Source:Sep 15, 2026, 11:30 UTC
BioVie announced topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for treating neurological symptoms associated with Long COVID, reporting statistically significant benefits in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise.
Sep 8, 2026, 14:03 UTC
BioVie Inc requested an End-of-Phase 2 meeting with the US Food and Drug Administration to advance its Phase 3 development program for bezisterim in Parkinson's disease.
Source:Aug 31, 2026, 12:00 UTC
BioVie Inc. completed the treatment phase of its ADDRESS-LC Phase 2 trial of bezisterim for neurological symptoms of Long COVID.
Aug 6, 2026, 11:30 UTC
BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson's disease, showing statistically significant improvements versus placebo on motor and non-motor symptoms.